FDA and FTC warned Beauty & Spa Concepts, DBA Beenefits, over unapproved, misbranded Brazilian Propolis Extract sold with COVID-19 prevention and treatment claims.
What happened
FDA reviewed www.beenefits.com on January 8, 2021, and FTC reviewed it on May 5, 2021; FDA also reviewed the company's Instagram page. The agencies found the site offered Brazilian Propolis Extract for sale and made claims that it could mitigate, prevent, treat, diagnose, or cure COVID-19.
What FDA found
The company sold Brazilian Propolis Extract as a new drug without FDA approval.
section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)The product was misbranded as a drug.
section 502 of the FD&C Act, 21 U.S.C. § 352The letter says introducing the product into interstate commerce is prohibited.
sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)The company advertised that the product could prevent, treat, or cure disease without competent and reliable scientific evidence.
FTC Act, 15 U.S.C. 41 et seq.
What FDA wants
FDA asks the company to take immediate action to stop selling any unapproved, unauthorized products for COVID-19 and to email COVID-19-Task-Force-CFSAN@fda.hhs.gov within 48 hours describing corrective steps and how it will prevent recurrence.
Who should pay attention
- sellers of propolis or other supplements making health claims
- online retailers and marketplaces hosting COVID-19 claims
- companies using Instagram testimonials in product marketing
This is a summary. Read the original letter on fda.gov.